Iovance Biotherapeutics, Inc. (IOVA) Guidance & Earnings Results
On 2026-08-06 Iovance Biotherapeutics, Inc. reaffirmed guidance: "Reviewing FY26 revenue guidance of $350M-$370M; update in…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IOVAIovance Biotherapeutics, Inc.Follow IOVA — free
—
Price chart with a free account
- Market cap
- 6.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Reaffirmed | Reviewing FY26 revenue guidance of $350M-$370M; update in Q3 · full year |
| 7 May 26 | Raised | Q2 2026 revenue guidance $86-88M; FY2026 $350-370M · full year |
| 24 Feb 26 | Reaffirmed | FY2025 revenue achieved guidance of $250M-$300M · full year |
| 6 Nov 25 | Reaffirmed | Full-year 2025 revenue $250-$300 million · full year |
| 7 Aug 25 | Reaffirmed | FY2025 total product revenue guidance $250-300 million · full year |
Iovance Biotherapeutics, Inc. — questions
- What guidance did Iovance Biotherapeutics, Inc. give?
- On 2026-08-06: "Reviewing FY26 revenue guidance of $350M-$370M; update in Q3"
- When does Iovance Biotherapeutics, Inc. report earnings?
- Iovance Biotherapeutics, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Iovance Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.